PRL and polycystic ovary syndrome: The most probable explanations for the inhibitory effect of PCOS on the prolactin-lowering properties of metformin are, however, interactions at the level of the pituitary adenosine 5′-monophosphate-activated protein kinase (AMPK) pathway or the tuberoinfundibular dopaminergic system.